- Home
- AMST vs APM Comparison
AMST vs APM Comparison
Compare AMST & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMST | APM |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.8M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AMST | APM |
|---|---|---|
| Price | $1.16 | $0.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 266.3K | ★ 283.3K |
| Earning Date | 05-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,459.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $0.65 |
| 52 Week High | $4.78 | $4.47 |
Technical Indicators
Market Signals| Indicator | AMST | APM |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 46.90 |
| Support Level | $0.88 | $0.76 |
| Resistance Level | $2.12 | $0.93 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 0.03 | 10.33 |
Price Performance
Historical ComparisonAbout AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About APM Aptorum Group Limited
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.